Founders Financial Securities LLC Makes New $957,000 Investment in Halozyme Therapeutics, Inc. $HALO

Founders Financial Securities LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 8,667 shares of the biopharmaceutical company’s stock, valued at approximately $957,000.

A number of other large investors have also modified their holdings of the stock. Hilton Head Capital Partners LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $33,000. CoreCap Advisors LLC lifted its position in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares in the last quarter. MidFirst Bank purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 in the last three months. 2.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on HALO. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.55.

Halozyme Therapeutics Price Performance

HALO opened at $130.91 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company’s 50-day moving average price is $113.70 and its 200 day moving average price is $83.45. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $134.00. The firm has a market cap of $14.86 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 0.49 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.